Comprising data from ACTG 175, a Phase III randomized, double-blind study evaluating the clinical efficacy of indinavir sulfate combined with zidovudine (AZT) and lamivudine (3TC) in AIDS patients. The study population consisted of subjects with HIV infection, CD4 cell counts <= 200 cells/mm3, and at least 6 months of prior AZT experience. The data was produced by the ACTG Statistical and Data Analysis Center.
Use Cases
- Analyze clinical efficacy outcomes for the indinavir sulfate treatment arm versus placebo in combination with AZT and 3TC.
- Investigate the relationship between prior AZT therapy duration and treatment response in the study population.
- Examine patient outcomes segmented by the baseline CD4 cell count threshold of <= 200 cells/mm3.
Strengths
- Data originates from a Phase III randomized, double-blind clinical trial, a gold-standard study design.
- Study focuses on a specific, advanced patient population with CD4 counts <= 200 cells/mm3 and prior AZT experience.
- The dataset is associated with the ACTG (Advancing Clinical Therapeutics Globally) network, a major HIV/AIDS research consortium.
Limitations
- Specific data structure (rows, columns, file formats) is unknown, limiting immediate usability for analysis.
- The dataset's age and temporal coverage are not specified, which may affect relevance to current treatment standards.
- Without column details, the scope of available variables (e.g., specific lab results, adverse events) is unclear.
Provenance
- Source
- ACTG Statistical and Data Analysis Center
- Collection Method
- Data collected from a randomized, double-blind, Phase III clinical trial.
- Time Range
- null
- Freshness
- null
- Geography
- null